Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › CABA

SUPERSTRING CAPITAL MANAGEMENT LP position in CABA

CABALETTA BIO INC · Health Care

SUPERSTRING CAPITAL MANAGEMENT LP reported holding 1,278,652 shares of CABA (CABALETTA BIO INC) in its Q2 2026 13F filing — a position valued at US$3.5M, representing 2.20% of its reported portfolio and ranking #19 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP has disclosed CABA holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.28M sh
Reported value held$3.48M
Portfolio Weight2.20%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SUPERSTRING CAPITAL MANAGEMENT LP's CABA position evolved

SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in CABA in Q1 2024 at 290,797 shares (US$5.0M). Across 10 filings, SUPERSTRING CAPITAL MANAGEMENT LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,278,652 shares valued at US$3.5M — an increase of 212,413 shares quarter over quarter.. Notable position changes include a 524% increase in Q4 2024 (shares fell 39% over the following quarter), a 131% increase in Q2 2025 (shares rose 54% over the following quarter), a 53% trim in Q1 2026 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 290.80K $4.96M New
Q2 2024 139.90K $1.05M Reduce
Q3 2024 131.79K $622.07K Reduce
Q4 2024 822.29K $1.87M Add
Q1 2025 458.97K $635.68K Reduce
Q2 2025 1.06M $1.61M Add
Q3 2025 1.54M $3.61M Add
Q4 2025 2.25M $4.94M Add
Q1 2026 1.07M $2.87M Reduce
Q2 2026 1.28M $3.48M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CABA and 13F data

CABA (CABALETTA BIO INC) is a Health Care company. 37 other funds we track also report a position in CABA — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$53.6M), Cormorant Asset Management, LP (US$15.6M), Opaleye Management Inc. (US$12.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CABA

All CABA fund holders →

FAQ

How long has SUPERSTRING CAPITAL MANAGEMENT LP held CABA?

SUPERSTRING CAPITAL MANAGEMENT LP has disclosed CABA holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in CABA?

As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 1.28M shares of CABA (CABALETTA BIO INC), valued at $3.48M, representing 2.20% of its reported portfolio and ranking #19.

Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling CABA?

In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP increased its position in CABA.

Which other funds hold CABA?

Other major institutional holders of CABA include Bain Capital Life Sciences Investors, LLC, Cormorant Asset Management, LP, Opaleye Management Inc., among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.